Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes
- 7 May 2014
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 231 (21) , 4135-4144
Abstract
Rationale Synthetic hallucinogenic tryptamines, especially those originally described by Alexander Shulgin, continue to be abused in the USA. The range of subjective experiences produced by different tryptamines suggests that multiple neurochemical mechanisms are involved in their actions, in addition to the established role of agonist activity at serotonin 2A (5-HT2A) receptors. Objectives This study evaluated the interaction of a series of synthetic tryptamines with biogenic amine neurotransmitter transporters and with serotonin (5-HT) receptor subtypes implicated in psychedelic effects. Methods Neurotransmitter transporter activity was determined in rat brain synaptosomes. Receptor activity was determined using calcium mobilization and DiscoveRx PathHunter® assays in HEK293, Gα16-CHO, and CHOk1 cells transfected with human receptors. Results Twenty-one tryptamines were analyzed in transporter uptake and release assays, and 5-HT2A, serotonin 1A (5-HT1A), and 5-HT2A β-arrestin functional assays. Eight of the compounds were found to have 5-HT-releasing activity. Thirteen compounds were found to be 5-HT uptake inhibitors or were inactive. All tryptamines were 5-HT2A agonists with a range of potencies and efficacies, but only a few compounds were 5-HT1A agonists. Most tryptamines recruited β-arrestin through 5-HT2A activation. Conclusions All psychoactive tryptamines are 5-HT2A agonists, but 5-HT transporter (SERT) activity may contribute significantly to the pharmacology of certain compounds. The in vitro transporter data confirm structure-activity trends for releasers and uptake inhibitors whereby releasers tend to be structurally smaller compounds. Interestingly, two tertiary amines were found to be selective substrates at SERT, which dispels the notion that 5-HT-releasing activity is limited only to primary or secondary amines.Keywords
This publication has 47 references indexed in Scilit:
- Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteersDrug and Alcohol Dependence, 2012
- Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic DrugsCell, 2011
- Nonlinear Pharmacokinetics of 5-Methoxy-N,N-dimethyltryptamine in MiceDrug Metabolism and Disposition, 2011
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effectsPsychopharmacology, 2011
- Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonistsNeuroscience Letters, 2011
- Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodentsPsychopharmacology, 2010
- When the Endogenous Hallucinogenic Trace AmineN,N-Dimethyltryptamine Meets the Sigma-1 ReceptorScience Signaling, 2009
- Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitorsPsychopharmacology, 2008
- Identification of a serotonin/glutamate receptor complex implicated in psychosisNature, 2008
- Agonist-directed signaling of the serotonin 2A receptor depends on β-arrestin-2 interactions in vivoProceedings of the National Academy of Sciences, 2008